FNY Investment Advisers LLC Invests $44,000 in ESSA Pharma Inc. (NASDAQ:EPIX)

FNY Investment Advisers LLC bought a new position in ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 25,000 shares of the company’s stock, valued at approximately $44,000. FNY Investment Advisers LLC owned 0.06% of ESSA Pharma as of its most recent filing with the SEC.

Separately, RTW Investments LP boosted its stake in ESSA Pharma by 41.9% in the 3rd quarter. RTW Investments LP now owns 3,261,496 shares of the company’s stock worth $19,765,000 after purchasing an additional 962,834 shares during the period. Institutional investors and hedge funds own 75.12% of the company’s stock.

ESSA Pharma Trading Down 0.6 %

EPIX opened at $1.76 on Thursday. The stock has a 50-day moving average of $1.74 and a 200 day moving average of $4.12. ESSA Pharma Inc. has a 12 month low of $1.40 and a 12 month high of $11.67. The firm has a market cap of $78.12 million, a P/E ratio of -2.84 and a beta of 1.61.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last released its earnings results on Tuesday, December 17th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. On average, research analysts forecast that ESSA Pharma Inc. will post -0.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EPIX shares. Piper Sandler downgraded shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $15.00 to $2.00 in a report on Monday, November 4th. Oppenheimer downgraded shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Finally, Jefferies Financial Group cut ESSA Pharma from a “buy” rating to a “hold” rating in a report on Monday, November 4th.

Insider Buying and Selling

In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the company’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $1.53, for a total value of $12,055,761.99. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 14.70% of the stock is owned by corporate insiders.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.